Alterations in the global proteome and phosphoproteome in third-generation EGFR TKI resistance reveal drug targets to circumvent resistance

Lung cancer is the leading cause of cancer mortality worldwide. The treatment of lung cancer patients harboring mutant EGFR with orally administered EGFR tyrosine kinase inhibitors (TKIs) has been a paradigm shift. Osimertinib and rociletinib are third-generation irreversible EGFR TKIs targeting the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Zhang, Xu, Maity, Tapan K., Ross, Karen E., Qi, Yue, Cultraro, Constance M., Bahta, Meriam, Pitts, Stephanie, Keswani, Meghana, Gao, Shaojian, Nguyen, Khoa Dang P., Cowart, Julie, Kirkali, Fatos, Wu, Cathy, Guha, Udayan
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8182571/
https://ncbi.nlm.nih.gov/pubmed/33727228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-20-2435
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados